| Patient | Ella Fitzgerald |
|---|---|
| Date of birth | 1917-04-25 |
| Identifiers | MRN HR-ML029-SYN-TD; SSN (made up) 000-29-3640 |
| Document date | 2026-11-01 |
| Author | Odessa Whitlow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit: diabetes with calf pain on walking, low glucose after late shows, eye and foot examinations, and cardiovascular risk. Concerns: Her calves cramp when she walks through airports and to the stage, and she is afraid of what that means for her legs; Her glucose has dropped low after late shows, once just before an encore; The vision in her right eye has blurred, and she worries about reading lyrics and set lists. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with breakfast and the evening meal | Oral route | 1977-03-01 | active | S |
| Glipizide 10 mg oral tablet, one tablet by mouth twice daily before meals | One tablet by mouth twice daily before breakfast and the evening meal | Oral route | 1982-09-01 to 1987-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime | 30 units at bedtime | Subcutaneous route | 1984-04-01 to 1987-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 24 units under the skin each morning | 24 units each morning, at the same clock time on tour, with written time-zone adjustments | Subcutaneous route | 1987-05-11 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 to 1987-05-11 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1987-05-11 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgery | Oral route | 1987-05-11 | active | S |
| Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose | One spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911 | Nasal route | 1987-05-11 | active | S |
| Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mg | One tablet by mouth twice daily, with aspirin 81 mg once daily | Oral route | 1987-05-26 | active | S |
| Semaglutide 0.25 mg under the skin once weekly for four weeks | 0.25 mg once weekly on the same day each week for four weeks | Subcutaneous route | 1987-08-10 to 1987-09-07 | completed | S |
| Semaglutide 0.5 mg under the skin once weekly | 0.5 mg once weekly on the same day each week | Subcutaneous route | 1987-09-07 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1987-08-10 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Advance care planning conversation, about 18 minutes | 1987-06-15 to 1987-06-15 | completed | S |
| Right-eye intravitreal anti-VEGF injection by the retina clinic (dose 1 of 3 monthly loading doses) | 1987-06-02 to 1987-06-02 | completed | S |
| Podiatry: reduction of calluses under the second metatarsal heads, nail care, and fitting for protective and low-heeled stage shoes | 1987-06-09 to 1987-06-09 | completed | S |
| Right-eye intravitreal anti-VEGF injection (dose 2 of 3) | 1987-06-30 to 1987-06-30 | completed | S |
| Right-eye intravitreal anti-VEGF injection (dose 3 of 3) | 1987-07-28 to 1987-07-28 | completed | S |
| Right-eye intravitreal anti-VEGF injection (first extended interval, six weeks) | 1987-09-08 to 1987-09-08 | completed | S |
| Podiatry: reduction of calluses and nail care, three-month review | 1987-09-14 to 1987-09-14 | completed | S |
| Right-eye intravitreal anti-VEGF injection (interval extended to eight weeks after this dose) | 1987-10-20 to 1987-10-20 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1987-06-15 | Pneumococcal conjugate vaccine (PCV20) | completed | S |
| 1987-10-26 | Influenza vaccine, high-dose, 1987-1988 season | completed | S |
| 1987-10-26 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1970s | Diabetes affecting her eyes, with health problems beginning in the 1970s | D (CLM-0007) |
| 1970s | Cataract surgery, after which she returned to touring more than 40 weeks a year | D (CLM-0008) |
| 1986 | Intensive care admission for heart trouble and quintuple-bypass heart surgery | D (CLM-0009) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died suddenly of a heart attack in 1932; age at death not recorded in the cited source | D (CLM-0002) |
| Concern | Status | Evidence |
|---|---|---|
| Her calves cramp when she walks through airports and to the stage, and she is afraid of what that means for her legs | active | S |
| Her glucose has dropped low after late shows, once just before an encore | active | S |
| The vision in her right eye has blurred, and she worries about reading lyrics and set lists | active | S |
Most recent measures: Hemoglobin A1c/Hemoglobin.total in Blood 7.1 on 1987-10-26; Sodium [Moles/volume] in Serum or Plasma 139 on 1987-10-26; Potassium [Moles/volume] in Serum or Plasma 4.5 on 1987-10-26; Creatinine [Mass/volume] in Serum or Plasma 0.94 on 1987-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M 65 on 1987-10-26; Glucose [Mass/volume] in Serum or Plasma 168 on 1987-05-11; Albumin/Creatinine [Mass Ratio] in Urine 18 on 1987-05-11; Cholesterol [Mass/volume] in Serum or Plasma 114 on 1987-10-26; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 48 on 1987-10-26; Cholesterol in HDL [Mass/volume] in Serum or Plasma 47 on 1987-10-26; Triglyceride [Mass/volume] in Serum or Plasma 96 on 1987-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 1987-05-11; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1987-05-11; Hemoglobin [Mass/volume] in Blood 12.4 on 1987-05-11; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 386 on 1987-05-11; Ankle-brachial index 0.74 on 1987-05-11; Toe brachial index - right 0.46 on 1987-05-11; Toe brachial index - left 0.55 on 1987-05-11; Visual acuity best corrected Right eye by ETDRS eye chart 75 on 1987-10-26; Visual acuity best corrected Left eye by ETDRS eye chart 81 on 1987-10-26; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1987-06-15; Total score [Mini-Cog] 5 on 1987-06-15; Total score [AUDIT-C] 1 on 1987-06-15 [S]
Strengths and supports: Supports and strengths: her music, her audiences, her band and road manager, and decades of experience of her own body on the road [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complications | active | confirmed | E11.51 | S — Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic. |
| Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problems | active | confirmed | E11.3311 | S — Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display. |
| Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgery | active | confirmed | I25.10 | S — Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1987-05-11 | Hemoglobin A1c/Hemoglobin.total in Blood | 8.6 | % | Below 5.7% is normal; her individualized goal is below 7.5% | High | S |
| 1987-05-11 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1987-05-11 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1987-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1987-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M | 67 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1987-05-11 | Glucose [Mass/volume] in Serum or Plasma | 168 | mg/dL | 70-99 mg/dL | High | S |
| 1987-05-11 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | <=30 mg/g | Normal | S |
| 1987-05-11 | Cholesterol [Mass/volume] in Serum or Plasma | 164 | mg/dL | <=199 mg/dL | Normal | S |
| 1987-05-11 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 92 | mg/dL | Her goal with coronary and peripheral artery disease is below 55 mg/dL | Normal | S |
| 1987-05-11 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 | mg/dL | >=50 mg/dL | Low | S |
| 1987-05-11 | Triglyceride [Mass/volume] in Serum or Plasma | 140 | mg/dL | <=149 mg/dL | Normal | S |
| 1987-05-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 1987-05-11 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 10-35 U/L | Normal | S |
| 1987-05-11 | Hemoglobin [Mass/volume] in Blood | 12.4 | g/dL | 11.6-15 g/dL | Normal | S |
| 1987-05-11 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 386 | pg/mL | 232-1245 pg/mL | Normal | S |
| 1987-05-11 | Ankle-brachial index | 0.62 | {ratio} | 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal | Low | S |
| 1987-05-11 | Ankle-brachial index | 0.74 | {ratio} | 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal | Low | S |
| 1987-05-11 | Toe brachial index - right | 0.46 | {ratio} | Above 0.70 normal | Low | S |
| 1987-05-11 | Toe brachial index - left | 0.55 | {ratio} | Above 0.70 normal | Low | S |
| 1987-05-11 | Visual acuity best corrected Right eye by ETDRS eye chart | 64 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Low | S |
| 1987-05-11 | Visual acuity best corrected Left eye by ETDRS eye chart | 81 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Normal | S |
| 1987-06-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1987-06-15 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 1987-06-15 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 1987-08-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.6 | % | Below 5.7% is normal; her individualized goal is below 7.5% | High | S |
| 1987-08-10 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1987-08-10 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1987-08-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1987-08-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M | 64 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1987-08-10 | Cholesterol [Mass/volume] in Serum or Plasma | 128 | mg/dL | <=199 mg/dL | Normal | S |
| 1987-08-10 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 64 | mg/dL | Her goal with coronary and peripheral artery disease is below 55 mg/dL | Normal | S |
| 1987-08-10 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=50 mg/dL | Low | S |
| 1987-08-10 | Triglyceride [Mass/volume] in Serum or Plasma | 112 | mg/dL | <=149 mg/dL | Normal | S |
| 1987-08-10 | Visual acuity best corrected Right eye by ETDRS eye chart | 71 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Low | S |
| 1987-08-10 | Visual acuity best corrected Left eye by ETDRS eye chart | 81 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Normal | S |
| 1987-10-26 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.1 | % | Below 5.7% is normal; her individualized goal is below 7.5% | High | S |
| 1987-10-26 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1987-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1987-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1987-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M | 65 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1987-10-26 | Cholesterol [Mass/volume] in Serum or Plasma | 114 | mg/dL | <=199 mg/dL | Normal | S |
| 1987-10-26 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 48 | mg/dL | Her goal with coronary and peripheral artery disease is below 55 mg/dL | Normal | S |
| 1987-10-26 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 47 | mg/dL | >=50 mg/dL | Low | S |
| 1987-10-26 | Triglyceride [Mass/volume] in Serum or Plasma | 96 | mg/dL | <=149 mg/dL | Normal | S |
| 1987-10-26 | Visual acuity best corrected Right eye by ETDRS eye chart | 75 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Low | S |
| 1987-10-26 | Visual acuity best corrected Left eye by ETDRS eye chart | 81 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1987-05-11 | Body height | 165 | cm | S |
| 1987-05-11 | Body weight | 84 | kg | S |
| 1987-05-11 | Body mass index (BMI) [Ratio] | 30.9 | kg/m2 | S |
| 1987-05-11 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1987-05-11 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1987-05-11 | Heart rate | 62 | /min | S |
| 1987-05-11 | Respiratory rate | 16 | /min | S |
| 1987-05-11 | Body temperature | 36.6 | Cel | S |
| 1987-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1987-05-26 | Body height | 165 | cm | S |
| 1987-05-26 | Body weight | 83.8 | kg | S |
| 1987-05-26 | Body mass index (BMI) [Ratio] | 30.8 | kg/m2 | S |
| 1987-05-26 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1987-05-26 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1987-05-26 | Heart rate | 60 | /min | S |
| 1987-05-26 | Respiratory rate | 16 | /min | S |
| 1987-05-26 | Body temperature | 36.5 | Cel | S |
| 1987-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1987-08-10 | Body height | 165 | cm | S |
| 1987-08-10 | Body weight | 82.1 | kg | S |
| 1987-08-10 | Body mass index (BMI) [Ratio] | 30.2 | kg/m2 | S |
| 1987-08-10 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1987-08-10 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1987-08-10 | Heart rate | 62 | /min | S |
| 1987-08-10 | Respiratory rate | 16 | /min | S |
| 1987-08-10 | Body temperature | 36.6 | Cel | S |
| 1987-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1987-10-26 | Body height | 165 | cm | S |
| 1987-10-26 | Body weight | 80.6 | kg | S |
| 1987-10-26 | Body mass index (BMI) [Ratio] | 29.6 | kg/m2 | S |
| 1987-10-26 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1987-10-26 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1987-10-26 | Heart rate | 60 | /min | S |
| 1987-10-26 | Respiratory rate | 16 | /min | S |
| 1987-10-26 | Body temperature | 36.6 | Cel | S |
| 1987-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1987-06-15 | Body height | 165 | cm | S |
| 1987-06-15 | Body weight | 83.4 | kg | S |
| 1987-06-15 | Body mass index (BMI) [Ratio] | 30.6 | kg/m2 | S |
| 1987-06-15 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1987-06-15 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1987-06-15 | Heart rate | 60 | /min | S |
| 1987-06-15 | Respiratory rate | 16 | /min | S |
| 1987-06-15 | Body temperature | 36.6 | Cel | S |
| 1987-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1987-05-11 | New patient visit: diabetes with calf pain on walking, low glucose after late shows, eye and foot examinations, and cardiovascular risk | finished | S |
| 1987-05-26 | Two-week review: glucose and hypoglycemia safety on the new plan, and vascular surgery consultation | finished | S |
| 1987-08-10 | Three-month review: A1c, lipids, walking program, eye treatment, and foot care | finished | S |
| 1987-10-26 | Five-and-a-half-month review: A1c, lipids, walking distance, revascularization decision, foot and eye follow-up | finished | S |
| 1987-06-15 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Comprehensive diabetic foot program: foot inspection, monofilament and vibration testing, and pulses at every visit; IWGDF risk category 2 with podiatry every three months for callus and nail care; protective daily shoes and low-heeled custom stage shoes; daily self-inspection with a magnifying mirror or her dresser's help; and same-day care for any blister, wound, or color change | completed | GL-IWGDF-2023, GL-ADA-2026, GL-CMID-2026 | S |
| Vascular surgery consultation for claudication with an ankle-brachial index of 0.62: arterial duplex, supervised exercise therapy, and whether and when revascularization should be considered, before any loss of tissue | completed | GL-ACC-PAD-2024, GL-IWGDF-PAD-2023 | S |
| Hypoglycemia safety on tour: glipizide stopped; glargine reduced 20% and moved to the morning, at a fixed clock time with written time-zone steps; a continuous glucose monitor with low alerts shared, with her consent, with her road manager; a glucose check before each show and a meal before late shows; glucose tablets in the dressing room and at the side of the stage; nasal glucagon with the road manager trained; and the beta-blocker's effect on warning signs explained | completed | GL-ADA-2026, GL-CMID-2026 | S |
| Glucose-lowering medicines with heart and kidney benefit: empagliflozin 10 mg started, with sick-day rules (hold on days she cannot eat or drink and before surgery), genital hygiene advice, and a foot check at each visit; metformin continued with vitamin B12 checked; A1c every three months until at goal (goal below 7.5%) | completed | GL-ADA-2026, GL-CMID-2026 | S |
| Cardiovascular protection: atorvastatin raised to 80 mg with a lipid panel 4 to 12 weeks later and a goal LDL below 55 mg/dL; aspirin and metoprolol continued; blood pressure goal below 130/80 mmHg | completed | GL-ADA-2026, GL-ACC-PAD-2024, GL-AHA-CCD-2023, GL-CMID-2026 | S |
| Eye care: retina clinic appointment within two weeks for the right macular edema, for anti-VEGF injections; retinal examination of both eyes at least yearly and more often while being treated; large-print materials | completed | GL-ADA-2026, GL-CMID-2026 | S |
| Kidney and laboratory monitoring: creatinine, eGFR and potassium at three months and then every six to twelve months, urine albumin-creatinine ratio yearly, liver tests after the statin change if symptoms, and vitamin B12 periodically on metformin | completed | GL-ADA-2026, GL-CMID-2026 | S |
| Access and equity: scheduling around tour dates, video visits on the road, large-print instructions, drug-cost checks before prescribing, coordination with clinics in tour cities, and diabetes self-management education and medical nutrition therapy timed to her touring | completed | GL-ADA-2026, GL-ACC-PAD-2024 | S |
| Supervised exercise therapy for claudication: treadmill walking to moderate calf pain, 30 to 45 minutes three times a week for twelve weeks at a hospital program, with a structured home walking plan for tour weeks; then walking at least three times a week for life | completed | GL-ACC-PAD-2024 | S |
| Low-dose rivaroxaban 2.5 mg twice daily with aspirin 81 mg to lower the risk of heart attack, stroke, and major limb events, with bleeding precautions and no anti-inflammatory painkillers | completed | GL-ACC-PAD-2024, GL-ADA-2026 | S |
| Revascularization plan: no procedure now; endovascular treatment of the right superficial femoral artery to be considered if claudication still limits her life after twelve weeks of supervised exercise and medical therapy; urgent vascular review for rest pain, a wound, or color change; ankle-brachial index and duplex at six months | completed | GL-ACC-PAD-2024, GL-IWGDF-PAD-2023 | S |
| Semaglutide 0.25 mg weekly for four weeks, then 0.5 mg weekly, for cardiovascular benefit and walking distance, with the retina clinic told before the start because a fast fall in glucose can briefly worsen retinopathy; ezetimibe 10 mg added for an LDL of 64 mg/dL | completed | GL-ADA-2026, GL-STRIDE-2025, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| No glucose below 70 mg/dL on most days and no level 2 or 3 low (below 54 mg/dL or needing help) through six months | 1987-10-26 | completed | No level 2 or 3 lows since intake; time below 70 mg/dL under 1% | S |
| A1c below 7.5% by six months | 1987-10-26 | completed | A1c 7.1% | S |
| LDL cholesterol below 55 mg/dL by six months | 1987-10-26 | completed | LDL 48 mg/dL on atorvastatin 80 mg and ezetimibe | S |
| Walk at least four blocks without stopping by six months | 1987-10-26 | completed | Walks about five blocks before calf pain | S |
| No foot ulcer, and protective footwear on and off stage, through six months | 1987-10-26 | completed | No ulcer; low-heeled custom stage shoes and protective daily shoes | S |